Robotic microscopy expedites bladder Ca diagnosis
The oncoFISH Bladder robotic digital microscopy system from Ikonisys (New Haven, CT) identifies and measures aneuploidy on chromosomes 3, 7, 9, and 17 in urine sediment specimens for diagnosis of initial and recurrent bladder cancer. Up to 170 prepared slides can be loaded, scanned, and the images captured in this walkaway system, which generates a gallery of images for review and interpretation. Select slide images and the analytical report can be transmitted to the urologist within 24 hours for diagnosis.
The oncoFISH Bladder robotic digital microscopy system from Ikonisys (New Haven, CT) identifies and measures aneuploidy on chromosomes 3, 7, 9, and 17 in urine sediment specimens for diagnosis of initial and recurrent bladder cancer. Up to 170 prepared slides can be loaded, scanned, and the images captured in this walkaway system, which generates a gallery of images for review and interpretation. Select slide images and the analytical report can be transmitted to the urologist within 24 hours for diagnosis. The system offers 98.5% concordance between manual and automated readings and 100% consistency in procedure, minimizing the potential for false-positive readings.
For more information, visit booth #1242 or www.ikonisys.com/I>.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
